계명대학교 의학도서관 Repository

Development of a prognosis-prediction model incorporating genetic polymorphism with pathologic stage in stage I non-small cell lung cancer: A multicenter study.

Metadata Downloads
Author(s)
Won Kee LeeShin Yup LeeJin Eun ChoiYangki SeokEung Bae LeeHyun Cheol LeeHyo‐Gyoung KangSeung Soo YooMyung Hoon LeeSukki ChoSanghoon JheonYoung Chul KimIn Jae OhKook Joo NaChi Young JungChang‐Kwon ParkMi‐Hyun KimMin Ki LeeJae Yong Park
Keimyung Author(s)
Park, Chang KwonJung, Chi Young
Department
Dept. of Internal Medicine (내과학)
Dept. of Thoracic & Cardiovascular Surgery (흉부외과학)
Journal Title
Thorcic Cancer
Issued Date
2017
Volume
8
Issue
3
Keyword
NSCLCpolymorphismprognosisstagesurgery
Abstract
Background;

This multicenter study was performed to develop a prognosis‐prediction model incorporating genetic polymorphism with pathologic stage for surgically treated non‐small cell lung cancer (NSCLC) patients.


Methods;

A replication study including 720 patients and a panel of eight single nucleotide polymorphisms (SNPs), which predicted the prognosis of surgically treated NSCLC in our previous study, was conducted. Using the combined cohort of current and previous studies including 1534 patients, a nomogram for predicting overall survival was made using Cox proportional hazards regression.


Results;

Among the eight SNPs, C3 rs2287845, GNB2L1 (alias RACK1), and rs3756585 were significantly associated with overall survival. A nomogram was constructed based on pathologic stage and the genotypes of the two SNPs, and the risk score was calculated for each patient in the combined cohort. Using the prognosis‐prediction model, we categorized patients into low, intermediate, and high‐risk groups, which had greater accuracy in predictive ability (log‐rank statistics = 54.66) than the conventional tumor node metastasis staging (log‐rank statistics = 39.56). Next, we generated a prognosis‐prediction model for stage I to identify a subgroup of potential candidates for adjuvant chemotherapy. Notably, 97 out of 499 stage IB patients were classified as high‐risk patients with a similar prognosis to stage II patients, suggesting the benefit of adjuvant chemotherapy.


Conclusions;

This prognosis‐prediction model incorporating genetic polymorphism with pathologic stage may lead to more precise prognostication in surgically resected NSCLC patients. In particular, this model may be useful in selecting a subgroup of stage IB patients who may benefit from adjuvant chemotherapy.
Keimyung Author(s)(Kor)
박창권
정치영
Publisher
School of Medicine
Citation
Won Kee Lee et al. (2017). Development of a prognosis-prediction model incorporating genetic polymorphism with pathologic stage in stage I non-small cell lung cancer: A multicenter study. Thorcic Cancer, 8(3), 251–259. doi: 10.1111/1759-7714.12434
Type
Article
ISSN
1759-7706
DOI
10.1111/1759-7714.12434
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/32579
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
1. School of Medicine (의과대학) > Dept. of Thoracic & Cardiovascular Surgery (흉부외과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.